

Innovative Oncology Platform


- Establishes new treatment modality, aligned with National Cancer Institute (NCI) natural product initiative
- Synergistic natural small molecules & novel small proteins demonstrate efficacy above Standard of Care (SOC) in multiple cancer indications
- No adverse effects
- Clear regulatory pathway

Competitive Advantages

- Dry powder, natural ingredients equals reduced cost, ease of regulation, manufacturing, distribution & administration; increasing global Total Addressable Market (TAM)
- Potential first-in-class combinations with other modalities:
 - Chemotherapy
 - Radiotherapy
 - Targeted therapies (e.g. cell, gene)
 - Immunotherapy
 - Surgery (pre & post)



Ovarian & Breast Cancer Cell Response



After 24 hours exposure to Pebble combination drug (C4+FI):
> 90% ovarian cancer cells dead
> 60% breast cancer cells dead

Partners

THE UNIVERSITY OF TEXAS
MD Anderson
Cancer Center®

KEMP
PROTEINS
QUALITY EXPRESSED

Allucent®
Helping bring new therapies to light

Principal Investigators (MD Anderson based)

- Head of Gynecologic Oncology and Co-lead Ovarian Cancer Moon Shot Program
- Head of Radiation Oncology

Corporate Team

- Management: biopharma & natural product expertise
- Board: finance expertise, including multiple exits

Executing FDA Pre-IND Gap Analysis

- **Lead Candidate:** two agent combination
- Outstanding Proof of Concept (POC) data in Ovarian, Breast
- Encouraging signals in Lung, Colorectal, Prostate, Leukemia
- Potential for **Fast Track** and **Orphan**.

Development Status

- Robust IP, owned by Pebble Life Science
- Patent family with multiple CIP's
- IND-enabling studies based on FDA INTERACT response (1Q25)

Seeking

- Seed Round (\$5M)
- Use of Funds:
 - Lead drug IND-enabling studies
 - cGMP Manufacturing
 - Staffing and Operations
 - Pre-IND meeting prep & meeting

Extending Runway



In discussions
for non-dilutive
collaboration

